Fulcrum Therapeutics, Inc. (FULC)
Nasdaq: FULC · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Feb 24, 2026 | Feb 25, 2025 | Feb 27, 2024 | Mar 9, 2023 | Mar 3, 2022 | Mar 4, 2021 | Mar 5, 2020 | · |
| Revenue | 0 | 80,000 | 2,805 | 6,342 | 19,163 | 8,823 | · | · |
| Research and development | 56,103 | 63,386 | 71,801 | 76,782 | 69,701 | 59,042 | 71,072 | 25,184 |
| General and administrative | 28,666 | 36,448 | 41,668 | 41,694 | 30,516 | 21,392 | 13,145 | 8,314 |
| Total operating expenses | 84,769 | 101,897 | 113,469 | 118,903 | 100,217 | 80,434 | 84,217 | 33,498 |
| Operating income | -84,769 | -21,897 | -110,664 | -112,561 | -81,054 | -71,611 | -84,217 | -33,498 |
| Interest income (expense), net | 9,889 | 12,172 | 13,329 | 2,690 | 207 | 792 | 1,540r | 518 |
| Income tax expense | 0 | 0 | · | · | · | · | · | · |
| Net income including non-controlling interests | -74,880 | -9,725 | -97,335 | -109,872 | -80,847 | -70,819 | -82,677 | -32,588 |
| Net income | -74,880 | -9,725 | -97,335 | -109,871 | -80,847 | -70,819 | -82,677 | -32,588 |
| Preferred dividends | · | · | · | · | · | · | 7,128 | 6,559 |
| Net income to common shareholders | · | · | · | · | · | -70,819 | -89,805 | -39,147 |
| Earnings per share, basic | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 | · | · |
| Earnings per share, diluted | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.29 | -2.79 | -8.13 | -31.14 |
| Weighted average shares, basic | 63,355 | 61,984 | 61,310 | 44,991 | 35,361 | 25,354 | · | · |
| Weighted average shares, diluted | 63,355,000b | 61,984,000b | 61,310,000b | 44,991,000b | 35,361,000b | 25,354,000b | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 35,361 | 25,354 | 11,046 | 1,257 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted